Investor’s Toolkit: Key Ratios for Assessing Mimedx Group Inc (MDXG)’s Performance

Kevin Freeman

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

Mimedx Group Inc (NASDAQ: MDXG) closed the day trading at $6.9 down -2.54% from the previous closing price of $7.08. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 1.68 million shares were traded. MDXG stock price reached its highest trading level at $7.13 during the session, while it also had its lowest trading level at $6.735.

Ratios:

For a better understanding of MDXG, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.05. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.41. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.

Upgrades & Downgrades

In the most recent recommendation for this company, Cantor Fitzgerald on July 02, 2024, initiated with a Overweight rating and assigned the stock a target price of $11. On March 07, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12. On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.Craig Hallum initiated its Buy rating on October 27, 2023, with a $12 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 06 ’25 when Maersk-Moller Kimberly sold 58,300 shares for $7.42 per share. The transaction valued at 432,329 led to the insider holds 236,982 shares of the business.

Kimberly Ann Maersk-Moller bought 68,587 shares of MDXG for $502,743 on Nov 06 ’25. On May 02 ’25, another insider, Capper Joseph H, who serves as the Chief Executive Officer of the company, bought 200,000 shares for $6.34 each. As a result, the insider paid 1,268,000 and bolstered with 529,530 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 1021904896 and an Enterprise Value of 898035904. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.27, and their Forward P/E ratio for the next fiscal year is 19.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.60 while its Price-to-Book (P/B) ratio in mrq is 4.28. Its current Enterprise Value per Revenue stands at 2.283 whereas that against EBITDA is 13.089.

Stock Price History:

The Beta on a monthly basis for MDXG is 1.57, which has changed by -0.2721519 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, MDXG has reached a high of $9.71, while it has fallen to a 52-week low of $5.79. The 50-Day Moving Average of the stock is -2.08%, while the 200-Day Moving Average is calculated to be -0.54%.

Shares Statistics:

Over the past 3-months, MDXG traded about 857.47K shares per day on average, while over the past 10 days, MDXG traded about 825290 shares per day. A total of 148.08M shares are outstanding, with a floating share count of 116.72M. Insiders hold about 21.19% of the company’s shares, while institutions hold 51.91% stake in the company. Shares short for MDXG as of 1765756800 were 4599063 with a Short Ratio of 5.36, compared to 1763078400 on 4681432. Therefore, it implies a Short% of Shares Outstanding of 4599063 and a Short% of Float of 3.8900003.

Earnings Estimates

. The current assessment of Mimedx Group Inc (MDXG) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.

Analysts are recommending an EPS of between $0.44 and $0.4 for the fiscal current year, implying an average EPS of $0.42. EPS for the following year is $0.25, with 2.0 analysts recommending between $0.29 and $0.2.

Revenue Estimates

5 analysts predict $106.93M in revenue for. The current quarter. It ranges from a high estimate of $111M to a low estimate of $99.5M. As of. The current estimate, Mimedx Group Inc’s year-ago sales were $92.91MFor the next quarter, 5 analysts are estimating revenue of $95M. There is a high estimate of $102.5M for the next quarter, whereas the lowest estimate is $82M.

A total of 5 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $411.6M, while the lowest revenue estimate was $400M, resulting in an average revenue estimate of $407.48M. In the same quarter a year ago, actual revenue was $348.88MBased on 5 analysts’ estimates, the company’s revenue will be $416.08M in the next fiscal year. The high estimate is $464.9M and the low estimate is $378M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.